Audit: QRS - FOXO4-DRI for Health & Longevity

Audit conducted on 06/08/2026 05:30 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (5 mg/kg ~3×/week, IV/IP in rodents, subcutaneous outside any study, intermittent low-concentration rounds), time-to-effect values (24–36 h, within days, weeks), benefit/risk tier items, gate items, 11 monitoring rows and 8 qualitative markers trace to ER lines 373–379, 428, 138–210, 238–298, 340–347, 454–477.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“None established” for human dose mirrors ER “There is no validated human protocol” / “no human dose has been established”; “No consensus range; only change from own baseline” mirrors ER line 465.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy/breastfeeding/under-18 remains under Contraindications, not Key Interactions; benefits retain their species framing (“in living animals”, “In aged animals”, “human cell populations”).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications (lines 318–347); Benefits from Expected Benefits; Risks from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor is surfaced as a gate item.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no author names in the QRS. Drug names (venetoclax, navitoclax/ABT-263, anakinra, canakinumab, dasatinib, doxorubicin, warfarin, apixaban, clopidogrel, rapamycin, metformin) all appear in ER lines 322–338 for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Detached, evidence-first register matching the ER; the ER’s own qualifiers about species and absence of human data are carried through.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and thresholds throughout, framed as observation rather than instruction.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	No imperatives anywhere in the sheet.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets are stated as ranges, not as instructions to act; gates are stated as conditions, not directives.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommend”, “advise” or equivalent in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where required to name a marker or a gate (eGFR, hs-CRP, p16INK4a, Child-Pugh); the At-A-Glance is fully plain-language.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, tier items and marker rationales are single clauses; no elaboration carried over from the ER.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Sheet assumes readiness to obtain, self-administer and monitor an unapproved research peptide, matching ER lines 136 and 236.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Full baseline panel, 11 markers including research-grade p16 assay and epigenetic age, and cycle-based re-testing are presented without hedging on effort or cost.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content is unambiguously aimed at a deliberate self-experimenter, not a general reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance leads with the absence of any human exposure and research-chemical status, which is the decisive signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; “vascular aging” and “brain aging” mirror the ER headings.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Injection”, “Intravenous or intraperitoneal”, “subcutaneous”, “senescent”, “spermatogenesis”; the plain wording in At-A-Glance is required by item 7.4 and reproduces the ER Conclusion’s own register.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified verbatim at QRS lines 446, 489, 531, 564, 581, 603, 634, 638–640, 770 and the four tier labels in both the Benefits and Risks cards.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_×4, stop_items, caution_items, risks_×4, marker_#name/target/why (11 rows), monitoring_cadence, qualitative_item# (8) all present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff of the QRS against [qrs_template] shows the head, all CSS, the website="evidence_review", website="audit" and website="full_review" spans, the structural comments and the footer disclaimer are byte-identical; only variable spans differ.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding a QRS variable is empty; every tier, gate, protocol, monitoring and qualitative source section carries content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Monitoring row labels reproduce the ER biomarker table’s first column verbatim (Platelet count, eGFR, Creatinine, Blood urea nitrogen, Alanine aminotransferase and aspartate aminotransferase, hs-CRP, Interleukin-6, Total and free testosterone, Urine albumin-to-creatinine ratio, p16INK4a expression in peripheral T cells, Epigenetic age estimate).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk items reproduce the ER sub-headings; monitoring labels reproduce the ER table rows; gate items reproduce the ER bullet leads.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS; the ER’s 🟩/🟥/🟨 and ⚠️ markers are correctly dropped and tiering is carried by the bold “High/Medium/Low/Speculative” labels and card CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is reduced to its minimum expressible form — tier items are bare ER sub-headings, gate items are stripped of all trailing rationale, marker rationales are single clauses of 5–10 words, qualitative items are 4–8 words. No further condensation is available without dropping content mandated by items 8.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	QRS lines 2–14; the comment opens on line 2, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, body or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: foxo4_dri_2026-0806-0006_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0806-0406.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: foxo4_dri_2026-0806-0006_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-3 and git_issue: 4832; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: FOXO4-DRI for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: FOXO4-DRI for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/06/2026, correctly derived from qrs_creation_date: 2026-0806-0406.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line (ER line 31) is correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Every clause maps to ER Conclusion line 501: the mechanism, the replicated culture result, the animal outcomes, the absence of human exposure, the absence of a dose, and the research-chemical status.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“sparing healthy cells” (ER 501, 110); “repeatedly in cell cultures” (ER 501 “one of the better-replicated findings”); “fur, movement, kidney filtering, arteries and hormone output” (ER 501); “No person has received it in a registered study” (ER 501, 242); “no human dose exists” (ER 371, 501); “sold as a research chemical” (ER 432, 501).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “senescent” is rendered as “worn-out cells refusing to die” and “senolytic” is avoided entirely.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear in the At-A-Glance.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to ER lines 330 and 341–347.
8.2	[stop_items] represent the Contraindications from the ER	🟢	The seven “Populations for whom the intervention should be avoided” bullets (ER 341–347) plus the BCL-2-family absolute contraindication (ER 330) are all present — eight of eight.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	QRS lines 567–576: eight discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing rationales (“on the direct experimental evidence of worsened outcomes”, “for whom the mechanism cannot work”, “given the reparative role of transiently senescent cells”, “since senescence programs participate in normal development”, “where the interplay … is entirely uncharacterised”) and the “— absolute contraindication outside oncological supervision” clause are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“WHO Group 1” severity class, “Within 6 weeks” time window, “eGFR below 30 mL/min/1.73 m²” threshold, “Child-Pugh Class B or C” staging, “(venetoclax, navitoclax)”, “(Li-Fraumeni syndrome)” and “anyone under 18” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication bullets; the only “>”-style symbols are numeric thresholds (“eGFR below 30”), which are values, not rankings.
8.7	If no [stop_items] are present the section is left empty	N/A	Eight stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to ER lines 322–338.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of the nine ER interaction bullets are carried; the ninth (BCL-2 family inhibitors, ER 330) is correctly excluded here because it appears under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	QRS lines 584–593: eight discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “— caution, …” / “— monitor, …” clause and every “Mitigation: …” sentence is stripped; no dash-trailing content remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six ER example-drug lists are preserved intact, including “(dasatinib, quercetin, fisetin, navitoclax/ABT-263)” and “(quercetin, fisetin, apigenin, curcumin, resveratrol, urolithin A)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheses contain only plain comma-separated drug lists; no ranking notation is used.
9.7	If no [caution_items] are present the section is left empty	N/A	Eight caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 371–379.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, route and dosing pattern are the three decision-relevant implementation variables in ER lines 373–379; time-of-day and pharmacogenetics are correctly left out as non-actionable (“no chronobiological data exist”, “no protocol has ever been stratified”).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects are present, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“None established” (ER 371); “Mice received 5 mg/kg about three times weekly” (ER 373); “Intravenous or intraperitoneal in rodents; subcutaneous outside any study” (ER 373, 379); “Repeated low-concentration rounds; selectivity erodes at higher exposure” (ER 373, 385).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Senescent-cell death, senescence markers and functional changes are the three time courses given in ER line 428.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	time_1 maps to the High-tier benefit (selective removal from human cell populations), time_2 to the Medium-tier benefit (reduced senescent-cell burden in living animals), time_3 to the Low-tier benefits (kidney filtering, fur, activity).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“24–36 hours / In cell culture, after exposure”; “Within days / Measured in mice”; “Weeks / Fur, activity and renal markers in mice” — all from ER line 428.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 428), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven items map to the ER sub-headings at lines 140–210.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans populated at QRS lines 533–557, matching the ER’s 1 / 3 / 5 / 3 tier distribution.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER sub-headings; the ER’s Magnitude: lines (11.73-fold selectivity, >50% cell removal, pulse wave velocity, histological fibrosis scores) and all body prose are excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span; the ER’s PMID citations and “⚠️ Conflicted” markers are dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All ten items map to the ER sub-headings at lines 240–298.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans populated at QRS lines 605–628, matching the ER’s 2 / 2 / 3 / 3 tier distribution.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER sub-headings; the ER’s Magnitude: lines (zero registered trials, right ventricular systolic pressure, ES2 3–7× potency) and body prose are excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; PMID citations and “⚠️ Conflicted” markers are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and rationales derive from the ER biomarker table at lines 454–466.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER table rows are present in order, with the ER’s “Optimal Functional Range” values reproduced exactly (200–350 × 10⁹/L, >90 mL/min/1.73 m², 0.7–1.0 / 0.6–0.9 mg/dL, 10–16 mg/dL, ALT 10–26 / AST 10–26 U/L, <0.5 mg/L, <1.5 pg/mL, 600–900 ng/dL and 15–25 pg/mL, <10 mg/g, no consensus range, epigenetic age below chronological age).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS line 763 reproduces ER lines 450 and 452: full baseline panel before exposure, safety subset at 2–4 weeks after a cycle, inflammatory and functional markers at 3 months, full panel every 6–12 months or before each cycle.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All eight items derive from the ER qualitative marker list at lines 470–477.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Eight of eight: sleep quality and total sleep time; daytime energy and mid-afternoon trough; cognitive clarity, word-finding and task-switching ease; joint stiffness on waking and time to resolve; exercise recovery time and next-day soreness; skin appearance, hair density and nail growth; injection-site appearance; libido and morning erections.

Issues 06/08/2026 05:30

Pass rate 100.00%. No issues found.

Issues 06/08/2026 05:24

1. 1.3 — Species qualifier dropped from benefits: benefits_low (lines 546–550) renders three ER headings without their species qualifier — “in Aged Animals”, “in Aged Male Animals” and “in Animals” become “improved fur density, physical responsiveness and voluntary activity”, “in aged males” and “improved aortic function and delayed vascular aging” — which strengthens the claims for a compound with no human data and is inconsistent with the first item in the same list, which retains “in aged animals”.
2. 1.1 — Platelet rationale inverts ER sense: marker_1_why (line 650) reads “Reported not to cause this class toxicity”, dropping the ER’s “Detects the class toxicity that FOXO4-DRI is specifically reported not to cause” (ER line 456), so the “Why” column no longer states why the marker is measured and “this class toxicity” has no antecedent in the QRS.

Fixes 06/08/2026 05:24

1. 1.3 — Species qualifier restored in benefits: benefits_low was rewritten to lead with “In aged animals:” so the species applies to all five items, and “spermatogenesis in aged males” became “spermatogenesis in males”, removing the implication that the testosterone and vascular results were obtained in humans.
2. 1.1 — Platelet rationale restored: marker_1_why changed from “Reported not to cause this class toxicity” to “Detects the class toxicity the peptide is reported not to cause”, restoring the ER’s sense of why the marker is measured and giving “class toxicity” a subject.

Issues 06/08/2026 05:13

1. 4.5 — One-page A4 budget exceeded: The populated sheet carries 8 contraindications, 8 key interactions, an 11-row monitoring table, 8 qualitative items, and a 5-item Low benefits tier; at the template’s print metrics this renders to roughly two A4 pages rather than one.

Fixes 06/08/2026 05:13

1. 4.5 — Protocol and Time-to-Effect sub-lines condensed: Trimmed action_1_sub, action_2_sub, action_3_sub and time_3_sub (e.g. “No validated human protocol; mice received 5 mg/kg about three times weekly.” → “Mice received 5 mg/kg about three times weekly.”), removing one rendered line from each Protocol grid row.
2. 4.5 — Low benefits tier de-duplicated: Rewrote benefits_low so “in aged animals” is stated once rather than three times, without dropping any of the five ER benefit headings.
3. 4.5 — Gate items shortened: Condensed the two longest decision-gate entries — “BCL-2 family inhibitors used in oncology (venetoclax, navitoclax)” → “BCL-2 family inhibitors (venetoclax, navitoclax)” and “Supplements with senolytic or senomorphic activity (…)” → “Senolytic or senomorphic supplements (…)” — while leaving all eight contraindications and all eight key interactions in place with their example-drug lists intact.
4. 4.5 — Platelet-count rationale tightened: Shortened marker_1_why from “Class toxicity the peptide is reported not to cause” to “Reported not to cause this class toxicity”, saving a wrapped line in the 11-row monitoring table while preserving the ER’s “reported not to cause” hedge.

Issues 06/08/2026 05:01

1. 1.3 — Hedging dropped in monitoring rationale: marker_11_why states “Composite readout of biological aging”, dropping the ER’s conditional “Provides a composite readout if senescent-cell clearance influences biological aging” (ER line 466), and marker_6_why upgrades the ER’s “is meant to reduce” to “should reduce” (ER line 461).

Fixes 06/08/2026 05:01

1. 1.3 — Restored ER hedging in monitoring rationales: marker_11_why changed from “Composite readout of biological aging” to “Composite readout if senescent-cell clearance influences biological aging”, and marker_6_why changed from “should reduce” to “is meant to reduce”, both matching the ER wording.

Issues 06/08/2026 04:56

1. 1.3 — eGFR rationale drops species qualifier: [marker_2_why] states “Most improved organ function; peptide concentrates there”, while the ER eGFR row reads “the function most improved in animals”; removing the qualifier strengthens an animal finding into an apparently human one.
2. 2.7 — Garbled hs-CRP rationale: [marker_6_why] reads “Tracks systemic inflammation clearance should reduce”, an ungrammatical phrase in which “clearance” has no referent; the ER source is “Tracks the systemic inflammation that senescent-cell clearance is meant to reduce”.

Fixes 06/08/2026 04:56

1. 1.3 — eGFR rationale species qualifier restored: Changed [marker_2_why] from “Most improved organ function; peptide concentrates there” to “Most improved organ function in animals; peptide concentrates there”, matching the ER’s “in animals” hedge.
2. 2.7 — hs-CRP rationale made grammatical: Changed [marker_6_why] from “Tracks systemic inflammation clearance should reduce” to “Tracks systemic inflammation that senescent-cell clearance should reduce”, restoring the missing referent from the ER wording.

Issues 06/08/2026 04:49

1. 4.5 — Over-budget sub and Why cells: action_2_sub (line 470), action_3_sub (line 483) and time_3_sub (line 524) carry two-sentence explanatory blocks, and action_3_sub’s closing sentence (“Every published protocol is intermittent.”) merely restates action_3_value (“Intermittent cycles”); the Monitoring “Why” cells (lines 652–771) likewise reproduce near-full ER sentences rather than condensed fragments, pushing the sheet past the one-A4-page budget.

Fixes 06/08/2026 04:49

1. 4.5 — Protocol route cell condensed: action_2_sub reduced from “Retro-orbital intravenous and intraperitoneal in rodents; outside any study, a 10 mg freeze-dried vial reconstituted with bacteriostatic water, subcutaneously.” to “Retro-orbital intravenous or intraperitoneal in rodents; subcutaneous outside any study.”
2. 4.5 — Dosing-pattern restatement removed: Dropped the closing sentence “Every published protocol is intermittent.” from action_3_sub, since it merely restated the cell’s own value “Intermittent cycles”.
3. 4.5 — Time-to-effect cell condensed: time_3_sub merged into a single clause: “Fur, activity, urea and creatinine in mice; no human time course exists.”
4. 4.5 — Monitoring “Why” column condensed: All eleven marker_#_why cells rewritten as short fragments rather than near-full ER sentences (e.g., “Detects the class toxicity FOXO4-DRI is reported not to cause” → “Class toxicity the peptide is reported not to cause”; “Composite readout if clearance influences biological aging” → “Composite readout of biological aging”).
5. 4.5 — p16 target cell condensed: marker_10_target shortened from “No consensus range; meaningful only as change from an individual’s own baseline” to “No consensus range; only change from own baseline”, keeping the ER’s cautious “No consensus range” phrasing.

Issues 06/08/2026 04:42

1. 1.3 — Species qualifier dropped in ALT/AST row: The Monitoring “Why” cell for Alanine aminotransferase and aspartate aminotransferase (marker_5_why) reads “Liver injury is what the peptide prevented; a rise is off-mechanism”, omitting the ER’s “in mice” and so presenting an animal-only finding as an unqualified claim.

Fixes 06/08/2026 04:42

1. 1.3 — Species qualifier restored in ALT/AST row: Changed marker_5_why from “Liver injury is what the peptide prevented; a rise is off-mechanism” to “Liver injury is what the peptide prevented in mice; a rise is off-mechanism”, restoring the ER’s species qualifier.

Issues 06/08/2026 04:33

1. 4.5 — Sheet overflows one A4 page: The populated sheet runs to roughly two A4 pages under the @media print rules (lines 377–391); the least-condensed content is the three Protocol sub-cells (lines 456–485), each carrying two full sentences, alongside several two-line marker rationales and a two-line cadence line.

Fixes 06/08/2026 04:33

1. 4.5 — Protocol sub-cells condensed: Rewrote all three action_#_sub cells to single compact clauses (e.g. “No validated human protocol. The published preclinical regimen gave mice 5 mg/kg approximately three times per week.” → “No validated human protocol; mice received 5 mg/kg about three times weekly.”), removing about two rendered lines from each cell of the Protocol panel.
2. 4.5 — Time-to-effect sub trimmed: Shortened time_3_sub from “Fur density, activity, plasma urea and creatinine in mice.” to “Fur density, activity, urea and creatinine in mice.”, keeping the “No human time course exists” caveat.
3. 4.5 — Monitoring rationales tightened: Condensed five marker “Why” cells (eGFR, blood urea nitrogen, ALT/AST, hs-CRP, interleukin-6) so each fits a single rendered line, without altering any marker name or target value.
4. 4.5 — Cadence line shortened: Reduced monitoring_cadence to one rendered line while preserving all four cadence points (baseline, 2–4 weeks, 3 months, 6–12 months).

Issues 06/08/2026 04:24

1. 1.2 / 1.3 — At-a-glance drops ER hedge: The ER Conclusion (line 501) confines “it does exactly that” to cell cultures and says the mouse results are what the peptide “has been linked to”, but [at_a_glance] (QRS lines 434-437) states it “does this repeatedly in cell cultures and in aging mice, where fur, movement, kidney filtering, arteries and hormone output improved”, converting a cautious association into a demonstrated in-vivo effect.

Fixes 06/08/2026 04:24

1. 1.2 / 1.3 — At-a-glance hedge restored: Rewrote [at_a_glance] so the demonstrated claim stays confined to cell cultures and the mouse findings carry the ER’s cautious association — “It does this repeatedly in cell cultures; in aging mice it is linked to better fur, movement, kidney filtering, arteries and hormone output” — replacing the previous “does this repeatedly in cell cultures and in aging mice, where … improved”. The rewrite remains at 60 words.

Issues 06/08/2026 04:16

1. 2.15 — Colloquial “lab-made” in At-A-Glance: [at_a_glance] (QRS line 434) opens with “A lab-made peptide”; “lab-made” is a colloquial clipping, and the ER’s own voice uses the formal “laboratory-made” (ER line 501).

Fixes 06/08/2026 04:16

1. 2.15 — Colloquial “lab-made” replaced: Changed the opening of [at_a_glance] from “A lab-made peptide” to “A laboratory-made peptide”, matching the ER’s own formal wording. Word count is unchanged at 60, so the 7.2 limit still holds.